IL273719B - Improved methods of cell culture for adoptive cell therapy - Google Patents

Improved methods of cell culture for adoptive cell therapy

Info

Publication number
IL273719B
IL273719B IL273719A IL27371920A IL273719B IL 273719 B IL273719 B IL 273719B IL 273719 A IL273719 A IL 273719A IL 27371920 A IL27371920 A IL 27371920A IL 273719 B IL273719 B IL 273719B
Authority
IL
Israel
Prior art keywords
improved methods
cell culture
adoptive
cell
therapy
Prior art date
Application number
IL273719A
Other languages
Hebrew (he)
Other versions
IL273719A (en
Original Assignee
Wilson Wolf Mfg Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/493,768 external-priority patent/US20130115617A1/en
Application filed by Wilson Wolf Mfg Corporation filed Critical Wilson Wolf Mfg Corporation
Publication of IL273719A publication Critical patent/IL273719A/en
Publication of IL273719B publication Critical patent/IL273719B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL273719A 2012-06-11 2020-03-31 Improved methods of cell culture for adoptive cell therapy IL273719B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/493,768 US20130115617A1 (en) 2009-12-08 2012-06-11 Methods of cell culture for adoptive cell therapy
PCT/US2013/045209 WO2013188427A1 (en) 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy

Publications (2)

Publication Number Publication Date
IL273719A IL273719A (en) 2020-05-31
IL273719B true IL273719B (en) 2022-01-01

Family

ID=49758673

Family Applications (4)

Application Number Title Priority Date Filing Date
IL288241A IL288241B2 (en) 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy
IL302514A IL302514B1 (en) 2012-06-11 2013-06-11 Improved cell culture methods for stress cell therapy
IL235739A IL235739B (en) 2012-06-11 2014-11-17 Improved cell culture methods for stress cell therapy
IL273719A IL273719B (en) 2012-06-11 2020-03-31 Improved methods of cell culture for adoptive cell therapy

Family Applications Before (3)

Application Number Title Priority Date Filing Date
IL288241A IL288241B2 (en) 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy
IL302514A IL302514B1 (en) 2012-06-11 2013-06-11 Improved cell culture methods for stress cell therapy
IL235739A IL235739B (en) 2012-06-11 2014-11-17 Improved cell culture methods for stress cell therapy

Country Status (8)

Country Link
EP (1) EP2859093A4 (en)
JP (5) JP2015519080A (en)
CN (2) CN104411819B (en)
AU (3) AU2013274416B2 (en)
CA (1) CA3243987A1 (en)
IL (4) IL288241B2 (en)
SG (2) SG10201610387QA (en)
WO (1) WO2013188427A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
IL288241B2 (en) * 2012-06-11 2023-10-01 Wilson Wolf Mfg Corporation Improved methods of cell culture for adoptive cell therapy
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
JP6493692B2 (en) 2013-03-15 2019-04-10 セルジーン コーポレイション Modified T lymphocytes
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
ES2995052T3 (en) * 2014-04-23 2025-02-05 Juno Therapeutics Inc Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
SG11201701111SA (en) * 2014-08-12 2017-03-30 Anthrogenesis Corp Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
CN106755023A (en) * 2015-10-15 2017-05-31 中国人民解放军军事医学科学院附属医院 Chimeric antigen receptor immunocyte with safety switch and preparation method and application
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
CN109843921B (en) 2016-07-07 2023-05-26 艾欧凡斯生物治疗公司 Programmed death 1 ligand 1 (PD-L1) binding protein and application method thereof
CN106119193B (en) * 2016-07-28 2019-10-29 上海闪锦生物科技有限公司 A kind of preparation method for the T cells with antigenic specificity having NK cell speciality concurrently
SMT202400133T1 (en) 2016-10-26 2024-05-14 Iovance Biotherapeutics Inc Restimulation of cryopreserved tumor infiltrating lymphocytes
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
MA46916A (en) 2016-11-17 2019-09-25 Iovance Biotherapeutics Inc RESTTUMORINFILTRIERENDE LYMPHOZYTEN UND VERFAHREN ZUR HERSTELLUNG UND VERWENDUNG DAVON
ES3055314T3 (en) 2017-01-06 2026-02-11 Iovance Biotherapeutics Inc Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
JP7780248B2 (en) 2017-01-06 2025-12-04 アイオバンス バイオセラピューティクス，インコーポレイテッド Expansion of tumor-infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs with TNFRSF agonists
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (en) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc Operations for the production of tumor-infiltrating lymphocytes and their use in immunotherapy
JP7349365B2 (en) 2017-05-10 2023-09-22 アイオバンス バイオセラピューティクス，インコーポレイテッド Expansion of tumor-infiltrating lymphocytes from liquid tumors and their therapeutic use
IL322309A (en) 2017-05-24 2025-09-01 Novartis Ag Antibody IL2 engrafted proteins and methods of use in the treatment of cancer”
AR112072A1 (en) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc METHODS OF USE OF INFILTRATING TUMOR LYMPHOCYTES IN DOUBLE REFRACTORY MELANOMA
CN111601883B (en) 2017-11-17 2024-06-21 艾欧凡斯生物治疗公司 Expansion of TILs from fine needle aspirates and small biopsies
JP2021503885A (en) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood
WO2019118873A2 (en) 2017-12-15 2019-06-20 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US12104172B2 (en) 2018-01-08 2024-10-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific t-cells
MA52667B1 (en) 2018-03-29 2024-07-31 Iovance Biotherapeutics, Inc. METHODS FOR PRODUCING TUMOR-INFILTRATING LYMPHOCYTES AND THEIR USES IN IMMUNOTHERAPY
MA52533A (en) 2018-04-27 2021-03-03 Iovance Biotherapeutics Inc CLOSED CIRCUIT PROCESS FOR THE AMPLIFICATION AND EDITING OF TUMOR INFILTRATION LYMPHOCYTE GENES AND THEIR USES IN IMMUNOTHERAPY
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3108657A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
TW202031273A (en) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 Treatment of nsclc patients refractory for anti-pd-1 antibody
EP3852524B1 (en) 2018-09-20 2023-06-28 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
JP7688575B2 (en) 2018-11-05 2025-06-04 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of NSCLC patients refractory to anti-PD-1 antibodies
US20230039976A1 (en) 2018-11-05 2023-02-09 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
KR20210091213A (en) 2018-11-05 2021-07-21 이오반스 바이오테라퓨틱스, 인크. Methods for generating tumor-infiltrating lymphocytes and their use in immunotherapy
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
US20220193131A1 (en) 2018-12-19 2022-06-23 Iovance Biotherapeutics, Inc. Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP7749561B2 (en) 2019-12-11 2025-10-06 アイオバンス バイオセラピューティクス，インコーポレイテッド Process for the production of tumor infiltrating lymphocytes (TIL) and methods of using same
CN115244173A (en) 2019-12-20 2022-10-25 英研生物(英国)有限公司 Apparatus and method for isolating tumor-infiltrating lymphocytes and use thereof
JP2023524639A (en) 2020-04-22 2023-06-13 アイオバンス バイオセラピューティクス，インコーポレイテッド Manufacturing adjustment system and adjustment method of cells for patient-specific immunotherapy
TW202208616A (en) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 Selection of improved tumor reactive t-cells
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022125941A1 (en) 2020-12-11 2022-06-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022133149A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
KR20240032711A (en) 2021-03-25 2024-03-12 이오반스 바이오테라퓨틱스, 인크. Methods and compositions for use in T-cell co-culture efficacy assays and cell therapeutics
JP2024515189A (en) 2021-04-19 2024-04-05 アイオバンス バイオセラピューティクス，インコーポレイテッド Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy - Patents.com
EP4377446A1 (en) 2021-07-28 2024-06-05 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
AR127482A1 (en) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
CA3243416A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2069541C (en) * 1992-05-26 2005-02-01 Cornelis J. M. Melief Induction of an antigen-specific t-lymphocyte response
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US7638325B2 (en) * 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
DK1623017T3 (en) * 2003-05-08 2011-01-10 Life Technologies Corp Generation and isolation of antigen-specific T cells
PL2327763T3 (en) * 2005-08-05 2018-08-31 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generation of antigen-specific T cells
JP2009213462A (en) * 2008-02-15 2009-09-24 Kist-Europe Forschungs Gmbh Cell modification method and cell modification device
CN102625832A (en) * 2009-08-24 2012-08-01 贝勒医学院 Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses
US8809050B2 (en) * 2009-12-08 2014-08-19 Wilson Wolf Manufacturing Methods of cell culture for adoptive cell therapy
US20130115617A1 (en) * 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
NZ616405A (en) * 2011-04-08 2015-11-27 Baylor College Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
AU2012305931B2 (en) * 2011-09-08 2017-09-07 Yeda Research And Development Co. Ltd Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
EP2791322A1 (en) * 2011-12-12 2014-10-22 Cell Medica Limited Process of expanding t cells
GB201121308D0 (en) * 2011-12-12 2012-01-25 Cell Medica Ltd Process
DK2812431T3 (en) * 2012-02-09 2019-10-14 Baylor College Medicine PEPTID MIXTURES FOR GENERATION OF WIDE SPECIFIC MULTIVIRAL CTLS
US20130217122A1 (en) * 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
CN102719399A (en) * 2012-04-28 2012-10-10 北京爱根生物科技有限公司 In vitro amplification method of self-specific T cell, prepared T cell system, pharmaceutical use of cell system and component monitoring method of cell system
AU2013262485B2 (en) * 2012-05-18 2017-12-14 Wilson Wolf Manufacturing, LLC Improved methods of cell culture for adoptive cell therapy
IL288241B2 (en) * 2012-06-11 2023-10-01 Wilson Wolf Mfg Corporation Improved methods of cell culture for adoptive cell therapy
CN113801895A (en) * 2013-09-23 2021-12-17 威尔逊沃夫制造公司 Improved method for genetically modifying animal cells
US10857182B2 (en) * 2016-09-23 2020-12-08 Memorial Sloan Kettering Cancer Center Generation and use in adoptive immunotherapy of stem cell-like memory T cells
WO2018055191A1 (en) * 2016-09-26 2018-03-29 Tessa Therapeutics Pte. Ltd. T cell expansion method
JP2020527044A (en) * 2017-07-13 2020-09-03 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Methods for enhancing the growth and immunosuppressive capacity of the CD8 + CD45RCLOW / -Treg population
CN114502180A (en) * 2019-07-29 2022-05-13 贝勒医学院 Antigen-specific T cell repertoire and methods of making and using same
KR20220048021A (en) * 2019-08-16 2022-04-19 베이롤 칼리지 오브 메드신 Third party virus-specific T cell compositions, methods for their preparation and methods for their use in antiviral prophylaxis
US12305186B2 (en) * 2020-05-27 2025-05-20 Angeles Therapeutics, Inc. Methods for expanding SARS-COV2-antigen-specific t cells, compositions and uses related thereto

Also Published As

Publication number Publication date
IL235739B (en) 2020-04-30
AU2022202172A1 (en) 2022-04-21
EP2859093A1 (en) 2015-04-15
SG10201610387QA (en) 2017-02-27
IL288241B2 (en) 2023-10-01
CA2873608A1 (en) 2013-12-19
AU2013274416A1 (en) 2015-01-15
IL302514B1 (en) 2025-12-01
IL288241A (en) 2022-01-01
IL273719A (en) 2020-05-31
IL235739A0 (en) 2015-01-29
CN110241086A (en) 2019-09-17
IL302514A (en) 2023-07-01
AU2019240684A1 (en) 2019-10-24
JP2025092558A (en) 2025-06-19
JP2018138059A (en) 2018-09-06
IL288241B1 (en) 2023-06-01
JP2015519080A (en) 2015-07-09
WO2013188427A1 (en) 2013-12-19
JP7244461B2 (en) 2023-03-22
JP2020174685A (en) 2020-10-29
JP2023065668A (en) 2023-05-12
CA3243987A1 (en) 2026-02-06
EP2859093A4 (en) 2016-08-17
AU2013274416B2 (en) 2019-07-04
CN104411819B (en) 2019-05-10
SG11201407819UA (en) 2014-12-30
CN104411819A (en) 2015-03-11

Similar Documents

Publication Publication Date Title
IL273719A (en) Improved methods of cell culture for adoptive cell therapy
IL235443A0 (en) Improved methods of cell culture for adoptive cell therapy
IL237527A0 (en) Devices and methods for culture of cells
IL220232A0 (en) Improved methods of cell culture for adoptive cell therapy
IL234095A0 (en) Culturing of mesenchymal stem cells
IL236672B (en) System and methods for preparation of adipose-derived stem cells
IL238024A0 (en) Methods of host cell modification
SG11201503579RA (en) Cell culture med
EP2971014A4 (en) Methods of cell culture
EP2971040A4 (en) Methods of cell culture
PL2683815T3 (en) Genetically modified cell and process for use of said cell
EP2729561A4 (en) Cell culture process
SG11201500417PA (en) Cell culture
GB201100180D0 (en) Tumour cell and tissue culture
IL235709A0 (en) Tumor cell isolation/purification process and methods for use thereof
GB2520899B (en) Method for discriminating differentiation degree of pluripotent stem cell
AP3754A (en) Method of culturing algae
ZA201407298B (en) Methods for induction of antigen-specific regulatory t cells
ZA201504388B (en) Method for culturing pluripotent stem cells
GB2501101B (en) Method of culturing algae
ZA201309109B (en) Methods of treating biomass
ZA201307857B (en) Culture medium for human mesenclymal stem cells
GB201211873D0 (en) Cell culture
HUP1100092A2 (en) Arrangement for production and using of biogas
IL229242A0 (en) Allogeneic tumor cell vaccination